检索结果-南通市图书馆

miR-206 Inhibits Renal Cell Cancer Growth by Targeting GAK

Journal of Huazhong University of Science and Technology(Medical Sciences) 2016年第6期36卷 852-858页

作者： Chao WEI Shen WANG zhang-qun ye Zhi-qiang CHEN Department of Urology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Urology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China

Renal cell cancer(RCC)remains one of the most lethal types of cancer in *** RNAs(mi RNAs)play key roles in the pathogenesis of *** role of mi R-206 in RCC has not been fully *** purpose of this study was to examine the role of mi R-206 in the regulation of proliferation and metastasis of RCC and the possible *** R-206 expression was detected by reverse transcription?quantitative polymerase chain reaction(RT-q PCR)in RCC cell lines(786-O and OS-RC-2 cells)and clinical ***[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]method,colony formation and transwell assay were used to detect the tumor-suppressing ability of mi R-206 in *** assay was performed to verify the precise target of mi *** results showed that the expression of mi R-206 was significantly down-regulated in RCC tissues and *** expression level of cyclin G-associated kinase(GAK),a master regulator of tumor proliferation and metastasis,was up-regulated with the decrease in mi R-206 in RCC tissues as well as RCC cell *** addition,the mi R-206 inhibitor promoted the proliferation,migration and invasion of 786-O and OS-RC-2 *** combined with luciferase and Western blot assays revealed that mi R-206 inhibited the expression of ***,mi R-206 regulates RCC cell growth partly through targeting *** study indicated that mi R-206 functions as a tumor suppressor in regulating the proliferation,migration and invasion of RCC by directly targeting GAK,and it holds promises as a potential therapeutic target for RCC.

关键词： miR-206 renal cell cancer G-associated kinase

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Reduced corporal fibrosis to protect erectile function by inhibiting the Rho-kinase/LIM-kinase/ cofilin pathway in the aged transgenic rat harboring human tissue kallikrein 1

引用

Asian Journal of Andrology 2017年第1期19卷 67-72页

作者： Kai Cui Yang Luan Tao Wang Li Zhuan Ke Rao Shao-Gang Wang zhang-qun ye Ji-Hong Liu Dao-Wen Wang Department of Urology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China Institute of Urology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China Department of Reproductive Medicine the First People's Hospital of Yunnan Province Kunming 650032 China Division of Cardiology Department of Internal Medicine Tengji Hospiial Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China.

Our previous studies have demonstrated that erectile function was preserved in aged transgenic rats （TGR） harboring the human tissue kallikrein 1 （hKLK1）, while the molecular level of hKLK1 on corporal fibrosis to inhibit age-related erectile dysfunction （ED） is poorly understood. Male wild-type Sprague-Dawley rats （WTR） and TGR harboring the hKLK1 gene were fed to 4- or 18-month-old and divided into three groups： young WTR （yWTR） as the control, aged WTR （aWTR）, and aged TGR （aTGR）. Erectile function of all rats was assessed by cavernous nerve electrostimulation method. Masson＇s trichrome staining was used to evaluate corporal fibrosis in the corpus cavernosum. We found that the erectile function of rats in the aWTR group was significantly lower than that of other two groups. Masson＇s trichrome staining revealed that compared with those of the yWTR and aTGR groups, the ratio of smooth muscle cell （SMC）/collagen （C） was significantly lower in the aWTR group. Immunohistochemistry and Western blotting analysis were performed, and results demonstrated that expression of a-SMA was lower, while expressions of transforming growth factor-β1 （TGF-β1）, RhoA, ROCK1, p-MYPT1, p-LIMK2, and p-cofilin were higher in the aWTR group compared with those in other two groups. However, LIMK2 and cofilin expressions did not differ among three groups. Taken together, these results indicated that the RhoA/ROCK1/LIMK/cofilin pathway may be involved in the corporal fibrosis caused by advanced age, and hKLK1 may reduce this corporal fibrosis by inhibiting the activation of this pathway to ameliorate age-related ED.

关键词： aged corporal fibrosis erectile dysfunction gene therapy hKLK1

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms： a meta-analysis

引用

Asian Journal of Andrology 2015年第1期17卷 124-134,I0011页

作者： Ming-Chao Li Zheng-Yun Wang Jun Yang Xiao-Lin Guo Tao Wang Shao-Gang Wang Ji-Hong Liu zhang-qun ye Department of Urology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China Department of Respiratory and Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.

We performed a meta-analysis to compare treatment with a combination of solifenacin plus tamsulosin oral controlled absorption system （TOCAS） with placebo or TOCAS monotherapy. The aim of the meta-analysis was to clarify the efficacy and safety of the combination treatments method for lower urinary tract symptoms （LUTS）. We searched for trials of men with LUTS that were randomized to combination treatment compared with TOCAS monotherapy or placebo. We pooled data from three placebo-controlled trials meeting inclusion criteria. Primary outcomes of interest included changes in International Prostate Symptom Score （IPSS） and urinary frequency. We also assessed postvoid residual, maximum urinary flow rate, incidence of urinary retention （UR）, adverse events. Data were pooled using random or fixed effect models for continuous outcomes and the ManteI-Haenszel method to generate risk ratio. Reductions in IPSS storage subscore and total urgency and frequency score （TUFS） were observed with solifenacin 6 mg plus TOCAS compared with placebo （P 〈 0.0001 and P 〈 0.0001, respectively）. Reductions in IPSS storage subscore and TUFS were observed with solifenacin 9 mg plus TOCAS compared with placebo （P= 0.003 and P = 0.0006, respectively）. Reductions in TUFS was observed with solifenacin 6 mg plus TOCAS compared with TOCAS （P = 0.01）. Both combination treatments were well tolerated, with low incidence of UR. Solifenacin 6 mg plus TOCAS significantly improved total IPSS, storage and voiding symptoms compared with placebo. Solifenacin 6 mg plus TOCAS also improved storage symptoms compared with TOCAS alone. There was no additional benefit of solifenacin 9 mg compared with 6 mg when used in combination with TOCAS.

关键词： combination therapy lower urinary tract symptoms solifenacin tamsulosin oral controlled absorption system

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia:a subgroup analysis of the TITAN trial

引用

Asian Journal of Andrology 2022年第2期24卷 161-166页

作者： Byung Ha Chung Jian Huang zhang-qun ye Da-Lin He Hirotsugu Uemura Gaku Arai Choung Soo Kim Yuan-Yuan zhang Yusoke Koroki Suyeon Jeong Suneel Mundle Spyros Triantos Sharon McCarthy Kim N Chi Ding-Wei ye Department of Urology Gangnam Severance HospitalYonsei University College of Medicine211 Eonju-roGangnam-guSeoul 135-271Korea Sun Yat-Sen Memorial Hospital Sun Yat-sen UniversityGuangzhou 510120China Wuhan Tongji Hospital Tongji Medical CollegeWuhan 430030China First Affiliated Hospital of Xi’an Jiaotong University Xi’an 719054China Kindai University Hospital Ōsakasayama 589-8511Japan Dokkyo Medical University Saitama Medical Center Saitama 2-1-50Japan Asian Medical Center University of UlsanSeoul 138-040Korea Janssen Medical Affairs Department Beijing 100025China Janssen Medical Affairs Department Tokyo 101-0065Japan Janssen Medical Affairs Department Seoul 140-012Korea Janssen Global Medical Affairs Department HorshamPA 08869USA Janssen Research and Development Spring HousePA 19477USA Janssen Research and Development RaritanNJ 08869USA BC Cancer and Vancouver Prostate Centre VancouverBC V5Z 1G1Canada Fudan University Shanghai Cancer Center Shanghai 200032China

Ethnicity might be associated with treatment outcomes in advanced prostate *** study aimed to evaluate the efficacy and safety of androgen deprivation therapy(ADT)combined with apalutamide in East Asians with metastatic castration-sensitive prostate cancer(mCSPC).The original phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen(TITAN)trial was conducted at 260 sites in 23 *** subgroup analysis included patients enrolled in 62 participating centers in China,Japan,and *** progression-free survival(PFS),time to prostate-specific antigen(PSA)progression,and PSA changes from baseline were compared between groups in the East Asian *** intent-to-treat East Asian population included 111 and 110 participants in the apalutamide and placebo groups,*** 24-month radiographic PFS rates were 76.1%and 52.3%in the apalutamide and placebo groups,respectively(apalutamide vs placebo:hazard ratio[HR]=0.506;95%confidence interval[CI],0.302–0.849;P=0.009).Median time to PSA progression was more favorable with apalutamide than placebo(HR=0.210;95%CI,0.124–0.357;P<0.001).Median maximum percentages of PSA decline from baseline were 99.0%and 73.9%in the apalutamide and placebo groups,*** most common adverse event(AE)was rash in the apalutamide group,with a higher rate than that in the placebo group(37.3%vs 9.1%).The most common grade 3 or 4 AEs were rash(12[10.9%])and hypertension(12[10.9%])for *** efficacy and safety of apalutamide in the East Asian subgroup of the TITAN trial are consistent with the global results.

关键词： apalutamide East Asia metastasis prostatic neoplasm survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Biofeedback therapy for chronic pelvic pain syndrome

引用

Asian Journal of Andrology 2003年第2期5卷 155-158页

作者： zhang-qun ye Dan CAI Ru-Zhu LAN Guang-Hui DU Xiao-Yi YUAN Zhong CHEN Yang-Zhi MA You-Ming HU Gui-Yun ZENG Department of Urology Tongji Hospital Tongji Medical College Huazhong University of Science and TechnologyWuhan 430030 China

Aim: To evaluate the efficacy of biofeedback therapy in patients with chronic pelvic pain syndrome (CPPS). Methods: From November 2001 to April 2002, patients visiting the Urological Outpatient Clinic of this Hospital were evaluated by means of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and classified by the NIH classification standard. Sixty-two patients of CPPS category Ⅲwere involved in this study. All patients had been treated by conventional approaches such as antibiotics and alpha-blockers for more than half a year without any improvement. The expressed prostatic secretion results were as follows: WBC 5 to 9/high power field, lipid +-+++and bacterial culture negative. Their NIH-CPSI were 12-40. All the 62 cases complained of micturitional irritation (frequency, urgency, splitted stream and sense of residual urine), 32 cases, of pain or discomfort at the testicular, penile, scrotal, pelvic or rectal region and 13 cases, of white secretion-dripping. The patients were treated by the Urostym Biofeedback equipment (Laborie Co., Canada) 5 times a week for 2 weeks with a stimulus intensity of 15 mA-23 mA and duration of 20 minutes. Results: Sixty patients were significantly improved or cured, while no significant improvement in the remaining 2. No apparent side effect was observed. The NIH-CPSI dropped to 6 to 14 with an average reduction of 21 (P<0.01). In the 60 improved cases, pain was relieved after 2-3 treatment courses and other symptoms disappeared after 4-5 courses. Conclusion: Biofeedback therapy is a safe and effective treatment for CPPS. Large randomized clinical trials are needed to confirm its efficacy and to explore the mechanism of action.

关键词： biofeedback therapy pelvic pain prostatitis chronic

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Does Postoperative Rehabilitation for Radical Cystectomy Call for Enhanced Recovery after Surgery?A Systematic Review and Metaanalysis

引用

Current Medical Science 2019年第1期39卷 99-110页

作者： Jun XIAO Meng WANG Wei HE Jing WANG Fan YANG Xue-you MA Yu ZANG Chun-guang YANG Gan YU Zhi-hua Wang zhang-qun ye Department of Urology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Nursing Department Huanghuai UniversityZhumadian 463000China

The aim of this review was to systematically compare the outcomes of enhanced recovery after surgery(ERAS)with standard care(SC)after radical *** performed a systematic search of PubMed,Ovid?Web of Science,and the Cochrane Library to identify studies published until September 2017 which involved a comparison of ERAS and SC.A meta-analysis was performed to assess the outcomes of ERAS versus *** studies including 8 prospective and 8 retrospective trials met the eligibility criteria.A total of 2100 participants were assigned to ERAS(1258 cases)or SC(842 cases).The time to first flatus passage[WMD=-0.95 days,95%Cl(-1.50,-0.41),P=0.0006],time until return to a regular diet[WMD=-2.15 days,95%Cl(-2.86,—1.45),P<0.00001]and the length of hospital stay[WMD=-3.75 days,95%Cl(-5.13,-2.36),P<0.00001]were significantly shorter,and the incidence of postoperative complications[OR=0.60,95%Cl(0.44,0.83),P=0.002],especially postoperative paralytic ileus[OR=0.43,95%Cl(0.30,0.62),P<0.00001]and cardiovascular complications[OR=0.28,95%Cl(0.09,0.90),P=0.03]was significantly lower in the ERAS group than those in the SC *** meta-analysis demonstrated that ERAS was associated with a shorter time to first flatus passage,return of bowel fimction,and the length of hospital stay than SC in patients undergoing radical cystectomy,as well as a lower rate of postoperative complications,especially paralytic ileus and cardiovascular complications.

关键词： enhanced recovery after surgery postoperative rehabilitation bladder cancer radical cystectomy meta-analysis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Apalutamide for metastatic castration-sensitive prostate cancer:final analysis of the Asian subpopulation in the TITAN trial

引用

Asian Journal of Andrology 2023年第6期25卷 653-661页

作者： Byung Ha Chung Jian Huang Hiroji Uemura Young Deuk Choi zhang-qun ye Hiroyoshi Suzuki Taek Won Kang Da-Lin He Jae Young Joung Sabine D Brookman-May Sharon McCarthy Amitabha Bhaumik Anildeep Singh Suneel Mundle Simon Chowdhury Neeraj Agarwal Ding-Wei ye Kim N Chi Hirotsugu Uemura Gangnam Severance Hospital Yonsei University College of MedicineSeoul 06273South Korea Sun Yat-Sen Memorial Hospital Sun Yat-Sen UniversityGuangzhou 510123China Yokohama City University Medical Center Minami-kuYokohamaKanagwa 232-0024Japan Severance Hospital Yonsei University College of MedicineSeoul 03722South Korea Tongji Hospital Tongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Toho University Sakura Medical Center Chiba 285-0841Japan Chonnam National University Hospital and Medical School Gwangju 61469South Korea Department of Urology The First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 710061China Prostate Cancer Center National Cancer CenterGoyang 10408South Korea Janssen Research and Development Spring HousePA 19002USA Ludwig Maximilians University Munich 80539Germany Janssen Research and Development RaritanNJ 08869USA Janssen Medical Affairs Asia PacificSingapore 118222Singapore Guy’s and St Thomas’NHS Foundation Trust London SE14YBUK University of Utah Huntsman Cancer Institute Salt Lake CityUT 84112USA Fudan University Shanghai Cancer Center Shanghai 200032China Vancouver Prostate Centre University of British ColumbiaVancouverBritish Columbia V6H 3Z6Canada Kindai University Faculty of MedicineOsaka-Sayama 589-8511Japan

The final analysis of the phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen(TITAN)trial showed improvement in overall survival(OS)and other efficacy endpoints with apalutamide plus androgen deprivation therapy(ADT)versus ADT alone in patients with metastatic castration-sensitive prostate cancer(mCSPC).As ethnicity and regional differences may affect treatment outcomes in advanced prostate cancer,a post hoc final analysis was conducted to assess the efficacy and safety of apalutamide in the Asian ***-driven endpoints were OS,and time from randomization to initiation of castration resistance,prostate-specific antigen(PSA)progression,and second progression-free survival(PFS2)on first subsequent therapy or *** endpoints were assessed using the Kaplan–Meier method and Cox proportional-hazards models without formal statistical testing and adjustment for *** Asian patients received once-daily apalutamide 240 mg(n=111)or placebo(n=110)plus *** a median follow-up of 42.5 months and despite crossover of 47 placebo recipients to open-label apalutamide,apalutamide reduced the risk of death by 32%(hazard ratio[HR]:0.68;95%confidence interval[CI]:0.42–1.13),risk of castration resistance by 69%(HR:0.31;95%CI:0.21–0.46),PSA progression by 79%(HR:0.21;95%CI:0.13–0.35)and PFS2 by 24%(HR:0.76;95%CI:0.44–1.29)relative to *** outcomes were comparable between subgroups with low-and high-volume disease at *** new safety issues were *** provides valuable clinical benefits to Asian patients with mCSPC,with an efficacy and safety profile consistent with that in the overall patient population.

关键词： apalutamide Asia event-driven analysis metastatic castration-sensitive prostate cancer overall survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml^-1

引用

Asian Journal of Andrology 2015年第6期17卷 1017-1021,I0012页

作者： Rui Chen Li-qun Zhou Xiao-Bing Cai Li-Ping Xie Yi-Ran Huang Da-Lin He Xu Gao Chuan-Liang Xu Qiang Ding Qiang wei Chang-Jun Yin Shan-Cheng Ren Fu-Bo Wang ye Tian Zhong-Quan Sun Qiang Fu Lu-Lin Ma Jun-Hua Zheng zhang-qun ye Ding-Wei ye Dan-Feng Xu Jian-Quan Hou Ke-Xin Xu Jian-Lin Yuan Xin Gao Chun-Xiao Liu Tie-Jun Pan Ying-Hao Sun Department of Urology Shanghai Changhai Hospital Second Military Medical University Shanghai 200433 China ~Department of Urology Peking University First Hospital Institute of Urology Peking University National Urological Cancer Center Beijing 100034 China Department of Health Care PLA Headquarters of the General Staff Guard Bureau Beijing 100017 China Department of Urology First Affiliated Hospital School of Medicine Zhejiang University Hangzhou 310003 Zhejiang China Department of Urology Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200127 China Department of Urology First Affiliated Hospital of Medical School Xi'an:liaotong University Xi'an 710061 China Department of Urology Huashan Hospital Fudan University Shanghai 200040 China Department of Urology West China Hospital Sichuan University Chengdu 610041 Sichuan China State Key Laboratory of Reproductive Medicine Department of Urology The First Affiliated Hospital of Nanjing Medical University Nanjing 210029 China Department of Urology Beijing-Friendship Hospital Capital Medical University Beijing 100050China Department of Urology Huadong Hospital Fudan University Shanghai 20040 China Department of Urology Shanghai :Jiao Tong University Affiliated Sixth People's Hospital Shanghai 200233 China Department of Urology Peking University Third Hospital Beijing 100083 China Department of Urology Tenth People's Hospital Tongji University Shanghai 200072 China Department of Urology Tongji Hospital TongjJ Medical College Huazhong University of Science and TechnologyWuhan 430030 China Fudan University Shanghai Cancer Center Department of Oncology Shanghai 200032 China Department of Urology Shanghai ChangzhengHospital Second Military Medical University Shanghai 200003 China Department of Urology The First Affiliated Hospital of Soochow University Suzhou 215006 China Department of Urology Peking University People's Hospital Beijing 100044 China Department of Urology Xiji

Percent free prostatic-specific antigen （%fPSA） has been introduced as a tool to avoid unnecessary biopsies in patients with a serum PSA level of 4.0-10.0 ng ml^-1, however, it remains controversial whether %fPSA is effective in PSA range of 10.1-20.0 ng ml^-1 in both Chinese and Western population. In this study, the diagnostic performance of %fPSA and serum PSA in predicting prostate cancer （PCa） and high-grade PCa （HGPCa） was analyzed in a multi-center biopsy cohort of 5915 consecutive Chinese patients who underwent prostate biopsy in 22 hospitals across China from January 1, 2010 to December 31, 2013. The indication for biopsy was PSA〉4.0 ng ml^-1 or/and suspicious digital rectal examination. Total and free serum PSA determinations were performed by three types of electrochemiluminescence immunoassays with recalibration to the World Health Organization standards. The diagnostics accuracy of PSA, %fPSA and %fPSA in combination with PSA （%fPSA ＋ PSA） was determined by the area under the receivers operating characteristic curve （AUC）. %fPSA was more effective than PSA in men aged ≥60 years old. The AUC was 0.584 and 0.635 in men aged ≥60 years old with a PSA of 4.0-10.0 ng ml^-1 and 10.1-20.0 ng ml^-1, respectively. The AUC of %fPSA was superior to that of PSA in predicting HGPCa in patients ≥60 years old in these two PSA range. Our results indicated that %fPSA is both statistically effective and clinical applicable to predict prostate biopsy outcome in Chinese patients aged ≥60 years old with a PSA of 4.0-10.0 ng ml^-1 and 10.1-20.0 ng ml^-1.

关键词： Chinese population diagnosis percent free prostate-specific antigen prostate cancer prostate carcinoma tumor antigen prostate-specific antigen

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Effects of tetrandrine on cytosolic free calcium concentration in corpus cavernosum smooth muscle cells of rabbits

引用

Asian Journal of Andrology 2006年第4期8卷 405-409,513-514页

作者： Ji-Hong Liu Jun Chen Tao Wang Bo Liu Jun Yang Xiao-Wen Chen Shao-Gang Wang Chun-Ping Yin zhang-qun ye Department of Urology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Department of Pharmacy Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China

Aim:To study the relaxation mechanisms of tetrandrine(Tet)on the corpus cavernosum smooth ***: The corpus cavernosum smooth muscle cells from New Zealand white rabbits were cultured in vitro.[Ca^(2+)]_i was measured by Fluorescence Ion Digital Imaging System,using Fluo-2/AM as a Ca^(2+)-sensitive fluorescent indicator. Results:Tet(1,10 and 100 μmol/L)had no effect on the resting [Ca^(2+)]_i(P>0.05).In the presence of extracellular Ca^(2+)(2.5 mmol/L),Tet(1,10 and 100 μmol/L)inhibited [Ca^(2+)]_i elevation induced by high K^+ and phenylephrine(PE) in a concentration-dependent manner(P0.05).However,Tet(100μmol/L)inhibited [Ca^(2+)]_i elevation induced by PE(P<0.05).Conclusion:Tet inhibited the Ca^(2+)influx from the extracellular site via voltage- activated Ca^(2+)channel and α_1-adrenoceptor-operated Ca^(2+)*** a high concentration,Tet might inhibit the cytosolic calcium pool release in cultured corpus cavernosum smooth muscle *** inhibitory action on [Ca^(2+)]_i might be one of the relaxation mechanisms of Tet on the corpus cavernosum smooth muscle.(Asian J Androl 2006 Jul;8:405-409)

关键词： tetrandrine penis smooth muscle cell free calcium corpus cavernosum erectile dysfunction

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Audiovisual Sexual Stimulation and RigiScan Test for the Diagnosis of Erectile Dysfunction

引用

Chinese Medical Journal 2018年第12期131卷 1465-1471页

作者： Tao Wang Li Zhuan Zhuo Liu Ming-Chao Li Jun Yang Shao-Gang Wang Ji-Hong Liu Qing Ling Wei-Min Yang zhang-qun ye Department of Urology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430030 China Institute of Urology Tongji-Hospital Tongji-Medical College Huazhong Llniversity of Science and TechnologyWuhan Hubei 430030 China Department of Reproductive Medicine The First People's Hospital of Yunnan Province Kunming Yunnan 650032 China

Background： Currently available evaluation criteria lbr penile tumescence and rigidity have been fraught with controversy. In tiffs study, we sought to establish normative Chinese evaluation criteria lbr penile tumescence and rigidity by utilizing audiovisual sexual stimulation and RigiScanTM test （AVSS-Rigiscan test） with the administration of phosphodiesterase-5 inhibitor. Methods： A total of 1169 patients （aged 18-67 years） complained of erectile dysfunction （ED） underwent AVSS-RigiScan test with the administration of phosphodiesterase-5 inhibitor. A total of 1078 patients whose final etiological diagnosis was accurate by means of history, endocrine, vascular, and neurological diagnosis, International Index of Erectile Function 5 questionnaire, and erection hardness score were included in the research. Logistic regression model and receiver operating characteristic curve analysis were performed to determine the cutoffvalue of the RigiScanTM data. Then, the multivariable logistic analysis was used in the selected variables. Results： A normal restllt is defined as one erection with basal rigidity over 60% sustained for at least 8.75 rain, average event rigidity of tip at least 43.5% and base at least 50.5%, average maximum rigidity of tip at least 62.5% and base at least 67.5%, △tumescence （increase of tumescence or maxinaum-mininaum tumescence） of tip at least 1.75 cm and base at least 1.95 cm, total tumescence time at least 29.75 rain, and times of total tumescence at least once. Most importantly, basal rigidity over 60% sustained for at least 8.75 min, average event rigidity of tip at least 43.5%, and base at least 50.5% would be the new normative Chinese evaluation criteria for penile tumescence and rigidity. By multivariable logistic regression analysis, six significant RigiScanTM parameters including times of total tumescence, duration of erectile episodes over 60%, average event rigidity of tip, Atumescence of tip, average event rigidity of base, and Atunaes

关键词： Audiovisual Sexual Stimulation-RigiScan Test Erectile Dysfunction Phosphodiesterase-5 Inhibitor

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：